Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Revenue (2016 - 2025)

Historic Revenue for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $211.0 million.

  • Ptc Therapeutics' Revenue rose 722.66% to $211.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 14919.46%. This contributed to the annual value of $806.8 million for FY2024, which is 1397.3% down from last year.
  • Per Ptc Therapeutics' latest filing, its Revenue stood at $211.0 million for Q3 2025, which was up 722.66% from $178.9 million recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Revenue peaked at $1.2 billion during Q1 2025, and registered a low of $116.7 million during Q2 2021.
  • For the 5-year period, Ptc Therapeutics' Revenue averaged around $242.3 million, with its median value being $196.7 million (2023).
  • In the last 5 years, Ptc Therapeutics' Revenue crashed by 3057.55% in 2024 and then surged by 45973.12% in 2025.
  • Ptc Therapeutics' Revenue (Quarter) stood at $165.2 million in 2021, then increased by 1.32% to $167.4 million in 2022, then soared by 83.41% to $307.1 million in 2023, then tumbled by 30.58% to $213.2 million in 2024, then fell by 1.02% to $211.0 million in 2025.
  • Its last three reported values are $211.0 million in Q3 2025, $178.9 million for Q2 2025, and $1.2 billion during Q1 2025.